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Nucleic acid ampliﬁcation test (NAAT)-based assays provide fast and sensitive results compared to
conventional TB tests. The performance of the new Abbott Molecular MTB assay for the qualitative
detection of MTB complex using the automated m2000™ system or manual sample preparation is
summarized in this paper. The assay detects eight MTB complex subspecies. The observed limit of
detection (LOD) when used to test an MTB H37Rv panel was 2.45 colony forming units (cfu)/mL, while
the claimed assay LOD with this MTB strain is 17 cfu/mL. No cross reactivity, or carryover were observed
in the study. The clinical sensitivity of the assay was 93% overall; 99% in smear positive, culture positive
specimens, and 81% in smear negative, culture positive samples. The clinical speciﬁcity was 97%. The
inhibition rate in the study was 0.34%. The data suggest that Abbott RealTime MTB is a reliable, robust
and sensitive assay for the molecular detection of MTB.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB) is caused by infection with Mycobacterium
tuberculosis (MTB) [1]. TB is spread most commonly when people
with pulmonary TB expel MTB from their lungs [1]. TB poses a
serious threat to public health and is second only to HIV/AIDS as the
greatest killer worldwide due to a single infectious agent [1]. In
2013, there were 9.0 million new cases of TB and 1.5 million [2]died
from the disease.
Nucleic acid ampliﬁcation tests (NAAT) for detection of MTB can
provide faster results as compared to culture and with higher
sensitivity as compared to smear microscopy. Because of these
attributes use of MTB NAAT has been recommended. CDC
recommended, “that NAA (nucleic acid ampliﬁcation) testing be9G, DP-1, 1300 E. Touhy Ave.,
9; fax: þ1 224 361 7507.
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Ltd. This is an open access article uperformed on at least one respiratory specimen from each patient
with signs and symptoms of pulmonary TB” [3].
The Abbott m2000™ system, a batch analyzer that can process
up to 96 samples in one run, has been used in numerous testing
laboratories throughout the world for infectious disease di-
agnostics including Abbott RealTime HIV, which is used for viral
load testing to facilitate HIV therapy monitoring [4]. The Abbott
RealTimeMTB assaywas developed for use on them2000™ system.
Key features of the Abbott RealTime MTB assay include the
following: (1) use of sputum and bronchial alveolar lavage (BAL), as
well as N-acetyl-L-cysteine [NALC] sediments prepared from
sputum and BAL, as specimen types, (2) use of chemical inactiva-
tion to reduce infectivity of MTB-containing specimens, (3) auto-
mated sample processing, (4) use of two MTB targets to minimize
the likelihood of false negative assay results caused by target gene
mutation or deletion, and (5) use of the multicopy target, IS6110, to
maximize assay sensitivity [5]. This paper summarizes the analyt-
ical and clinical performance of the assay observed during devel-
opment of Abbott RealTime MTB.
2. Materials and methods
The workﬂow for the Abbott RealTime MTB assay is described in
Figure 1.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Workflow of Abbott RealTime MTB
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Figure 1. Workﬂow of Abbott RealTime MTB.
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500 mL of Inactivation reagent (IR) was prepared by combining
the following components: 20 mL 10 M NaOH, 300 mL isopropanol,
0.9 mL Tween-20, and 179.1 mL puriﬁed water. Once prepared the
IR was stable for up to one month at room temperature. If frozen,
specimens (unprocessed specimens or processed NALC sediments)
were thawed at 15 to 30 C. Approximately three volumes of IR
were added to each volume of sample (the minimum allowable
specimen volume is 0.3 mL). The same volume ratio of sample: IR
was maintained notwithstanding the type of sample (unprocessed
or NALC sediment). The mixture was vortexed twice for 20e30 s
each during the ﬁrst hour of room temperature incubation. The
validated incubation time was one to 24 h. The inactivation process
should occur under a biohood. Once completed, the inactivated
samples can be removed from under a biohood and then subjected
to sample preparation outside of the biohood. The inactivation
process was demonstrated to effectively reduce MTB viability at
three different laboratories using cultured MTB added to NALC
sediments of sputum, MTB positive clinical NALC sediments, and
MTB smear/culture positive sputum samples. This data has been
presented [11] and has been submitted for publication [6].
2.2. Sample preparation
IR-treated specimens and the assay controls were loaded onto
an m2000sp instrument where DNA was isolated using guanidi-
nium thiocyanate-magnetic microparticle technology to capture
nucleic acids followed by washes to remove unbound components.
An Internal Control (IC) was added at the start of sample prepara-
tion. The bound nucleic acids were eluted and transferred to a 96
deep-well plate. At the completion of sample preparation, the
m2000spwas used to create an ampliﬁcation mastermix consisting
of AmpliTaq Gold Polymerase, a magnesium chloride activation
reagent, and oligonucleotide reagent containing primers, probes
and dNTPs. Them2000spwas used to dispense 25 mL aliquots of the
mastermix followed by 25 mL aliquots of the extracted eluates to a
96-well optical reaction plate. The plate was sealed manually and
transferred to them2000rt for realtime PCR. As an alternative to the
m2000sp, sample preparation, mastermix preparation, and PCR
plate set-up can be performed manually.
2.3. Ampliﬁcation and detection
The m2000rt instrument was used for ampliﬁcation and real-
time ﬂuorescence detection. The detection of MTB complex mem-
bers [7] was achieved through the use of two sets of primers; onetargeting the insertion element IS6110 [5] and one the PAB gene [8].
Signal for MTB complex detection was generated with the use of
ﬂuorescent labelled probes. The MTB dual target probes are each
labeled with the ﬂuorophore FAM at the 50 end and the Black Hole
Quencher (BHQ1) at the 30 end. Thus MTB signals from both IS6110
and PAB are detected in the same FAM channel. The ampliﬁcation
cycle at which FAM ﬂuorescent signal is detected is proportional to
the log of the MTB DNA concentration present in the original
sample. The probe for internal control (IC) is labelled with Quasar at
the 50 and Black Hole Quencher BHQ2 at the 30 end to allow IC and
target signals to be distinguishable in a single PCR well.
2.4. Assay controls
A minimum of one replicate of the Negative Control and one
replicate of the Positive Control were used to determine run val-
idity. The Negative Control consisted of TE buffer and preservatives.
The Positive Control consisted of plasmid DNA containing both the
IS6110 and PAB target sequences diluted in TE buffer with 1.5 g/mL
of poly dA:dT and preservatives. The IC consisted of plasmid DNA
containing a pumpkin hydroxypyruvate reductase (HPR) sequence
insert diluted in TE buffer with 1.5 g/mL of poly dA:dT and pre-
servatives. IC was added at the start of sample preparation, serving
as a control for sample preparation recovery, sample inhibition, and
ampliﬁcation efﬁciency. The IC did not control for the inactivation
procedure. The IC threshold cycle (Ct) value difference between
each sample and the run controls was used to assess the validity of
each sample result.
2.5. Panels and clinical specimens
2.5.1. MTB complex subspecies
Nineteen MTB complex subspecies DNA samples were obtained
from the American Type Culture Collection (ATCC, Manassas, VA)
and one (Mycobacterium canettii) was provided kindly by Ibis Bio-
sciences (Carlsbad, CA). A total of 20 MTB complex strains were
tested including Mycobacterium africanum 25420, M. africanum
35711, Mycobacterium bovis 35735, M. bovis 19274, M. bovis BCG
35746,M. bovis BCG 35747D,M. canettii,Mycobacterium caprae BAA-
824D, Mycobacterium microti 11152, M. microti 19422, Mycobacte-
rium pinnipedii BAA-688D, MTB 25177D-5 (H37Ra), MTB 25618D-5
(H37Rv), MTB BAA-2236D, MTB BAA-2237D, MTB 27294D, MTB
BAA-2234D, MTB 35822D, MTB 35838D, MTB BAA-2235D. Addi-
tionally, 46 strains of the MTB subspecies including the three
principal genetic groups and nine genetic clusters were obtained
from Dr. Barry Kreiswirth at the University of Medicine and
Dentistry New Jersey (Newark, NJ) [9]. The DNA of the 20 MTB
complex subspecies obtained from ATCC and Ibis were directly
tested using reported DNA concentrations as determined by the
PicoGreen® NanoDrop method. The other 46 DNA concentrations
were determined using PicoGreen® NanoDrop measurements at
Abbott Molecular with the exception of three samples where such
measurements could not be obtained due to low volume and im-
purities. These three samples were diluted at a sample to water
ratio of 1:600 and tested directly.
2.5.2. Limit of detection [LOD]
An MTB H37Rv panel targeted to 1  105 colony forming units
(cfu)/mL was prepared by Zeptometrix (Buffalo, NY). Three one mL
aliquots of the Zeptometrix panel were combined and centrifuged
at 3000 g for 15 min to remove free MTB DNA in the supernatant.
The cell pellet was resuspended in threemL of TE buffer tomaintain
the concentration of 1  105 cfu/mL. The cells were then added to a
pool of sputum, which was homogenized using bead-beating, to
make the following MTB-containing dilution panels: 80 cfu/mL,
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0.10 cfu/mL, and 0.05 cfu/mL.2.5.3. Analytical speciﬁcity
Analytical speciﬁcity panel members were collected as follows:
Cytomegalovirus, Herpes Simplex virus 1, and Varicella-zoster virus
were obtained from Advanced Biotechnology Inc. (Columbia, MD),
69 mycobacterial and other microorganism species were obtained
from ATCC, and eight bacterial isolates were cultured at Abbott
Molecular.2.5.4. Potentially interfering substances
The following materials were obtained for this testing: blood,
DNA from human cells, gastric acid, hypertonic saline, physiologic
saline, culture media, NALC pellet material, ﬁve anti-TB medica-
tions (Isoniazid, Rifampicin, Streptomycin, Pyrazinamide, Etham-
butol), and bovine mucus.2.5.5. Carryover
Two samples were prepared: a high positive MTB sample con-
taining 1  107 copies/mL of a plasmid containing the assay target
sequences and a negative sample.2.5.6. Reproducibility
Two samples were prepared: a positive sample containing an
MTB concentration of approximately three times the claimed assay
LOD and a negative sample.2.5.7. Clinical specimens
198 Sputum specimens were collected by Discovery Life Sci-
ences (Los Osos, CA) from TB suspect patients in Russia, South Af-
rica, Uganda, and Vietnam. 150 sputum specimens from Vietnam
were obtained from the specimen bank operated by the Foundation
for Innovative New Diagnostics (FIND) (Geneva, Switzerland). 234
NALC specimens were obtained from Northwestern University
Memorial Hospital (Chicago, IL). All patient specimens were
collected under ethical guidelines. The HIV status of the patients
was not determined. For all specimens smear (when available) and
culture testing was performed near the collection site, while Abbott
RealTime MTB assay testing was performed at Abbott Molecular.Figure 2. Mean cycle number values determined when MTB complex genomic DNAs were te
CN value for each DNA and concentration tested are shown in the ﬁgure. All four replicates
replicates of 17 of the DNAs were positive when 10 genomes/reaction were tested. For three
positive when 10 genomes/reaction were tested.3. Results
3.1. MTB complex subspecies detection
This study was conducted to determine whether the speciﬁc
primers and probes used in Abbott RealTime MTB assay would
detect the following eight MTB complex sub-species:M. africanum,
M. bovis, M. bovis BCG, M. canettii, M. caprae, M. microti,
M. pinnipedii, and M. tuberculosis [6]. Two sets of puriﬁed MTB
complex DNAs were tested. The ﬁrst set of 20 puriﬁed DNAs con-
tained representatives of the previously mentioned MTB sub-
species. Each puriﬁed DNA was tested at two concentrations (100
and 10 genomes/reaction) with four replicates being tested per
concentration. At the 100 MTB genomes per reaction level, all four
replicates of each of the 20 MTB strains were detected. At the 10
MTB genomes per reaction level, all four replicates of 17 of the
strains were detected. For three strains (two M. bovis and one
M. bovis BCG) two of the four replicates were detected (Figure 2).
The second set of 46 MTB strains from the MTB sub-species were
tested at two concentrations: 100 genomes/reaction and 25 ge-
nomes/reaction. Four replicates of each DNA were tested at each
concentration. All the tested replicates were positive at both con-
centrations (Figure 3).
3.2. Limit of detection (LOD)
A nine-level dilution series was made from MTB strain H37Rv
cells diluted in a glass bead homogenized sputum pool. The panel
members in the dilution series were targeted to the following
concentrations: 80 cfu/mL, 50 cfu/mL, 25 cfu/mL, 10 cfu/mL, 5 cfu/
mL, 1 cfu/mL, 0.50 cfu/mL, 0.10 cfu/mL, and 0.05 cfu/mL. Twenty
replicates of each panel member were tested across four runs
using the Abbott RealTime MTB assay. The study was conducted
using one lot of Abbott RealTime MTB assay and control reagents.
The signiﬁcance level for this study was 0.05. The detection rate
was calculated for each target concentration (Table 1). A Probit
regression model was ﬁtted, based on the target concentrations
and the detection rate using PROC PROBIT in SAS, with the target
concentration (X) as the independent variable and the detection
rate P (Y ¼ 1) as the response variable. The Probit analysis of the
data determined that the concentration of MTB detected with 95%
probability was 2.45 cfu/mL (95% CI 1.44e6.10 cfu/mL). Thested to determine assay inclusivity. Four replicates were tested for each DNA. The mean
of each of the 20 DNAs were positive when 100 genomes/reaction were tested. All four
strains (two M. bovis and one M. bovis BCG) only two out of four replicates tested were
Figure 3. Mean cycle number values determined when MTB sub-species genomic DNAs were tested to determine assay inclusivity. Four replicates were tested for each DNA. The
mean CN value for each DNA and concentration tested are shown in the ﬁgure. All four replicates of each of the 43 DNAs were positive when 100 genomes/reaction and 25 genomes/
reaction were tested. Not included are the three DNAs for which DNA concentrations were not determined.
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17 cfu/mL in pooled homogenized sputum using the MTB H37Rv
strain.Table 2
Microorganisms tested to determine analytical speciﬁcity.
Species
Mycobacterium abscessus Mycobacterium
sphagni
Escherichia coli
Mycobacterium asiaticum Mycobacterium
szulgai
Haemophilus inﬂuenzae
Mycobacterium
austroafricanum
Mycobacterium terrae Herpes simplex
virus 1
Mycobacterium avium M. thermoresistibile Klebsiella pneumoniae
Mycobacterium avium ssp.
avium
Mycobacterium
tokaiense
Lactobacillus delbrueckii
Mycobacterium avium ssp.
paratuberculosis
Mycobacterium
ulcerans
Legionella pneumophila3.3. Analytical speciﬁcity
Each of the 80 potential cross-reactants was tested in both a
MTB positive sample and a MTB negative sample. Nucleic acid from
each potentially cross-reacting mycobacterium, virus, or other
microorganism at a targeted concentration of 1  105 to 1  107
copies or genomes per mL was added to the MTB positive samples
(containing 1000 MTB genomes/mL) and the MTB negative sam-
ples. Cultured microorganisms at a target concentration of
1  106 cfu/mL were added to the MTB positive samples and the
MTB negative samples. The assay results for all 80 negative samples
were reported as “MTB Not Detected”. The assay results for all 80
MTB-containing samples were reported as “MTB Detected”
(Table 2).Mycobacterium celatum Mycobacterium
vaccae
Neisseria gonorrhoeae
Mycobacterium chelonae Mycobacterium
xenopi
Neisseria meningitidis
Mycobacterium chitae Acinetobacter
baumannii
Porphyromonas gingivalis
Mycobacterium fallax Aeromonas hydrophila Proteus mirabilis
Mycobacterium ﬂavescens Bacillus cereus Pseudomonas aeruginosa
Mycobacterium fortuitum Bacillus subtilis Salmonella choleraesuis
Mycobacterium gastri Bordetella
parapertussis
Serratia marcescens
Mycobacterium gordonae Campylobacter jejuni Staphylococcus aureus
Mycobacterium
intracellulare
Candida albicans Staphylococcus epidermidis3.4. Potentially interfering substances
The potential for interference in the test results was assessed
with substances thatmay be present in the respiratory system. MTB
negative and MTB positive (500 copies/mL) samples were tested in
the absence or the presence of each potentially interfering sub-
stance with elevated levels of bovine mucus, blood, DNA from hu-
man cells, gastric acid, hypertonic saline, physiological saline,
culture media, NALC pellet material and ﬁve anti-TB medications
(Isoniazid, Rifampicin, Streptomycin, Pyrazinamide, Ethambutol)Table 1
Limit of detection.
Target concentration
(cfu/mL)
Number
tested
Number
detected
Detection
rate
Percent
detected
80 20 20 1.00 100
50 20 20 1.00 100
25 20 20 1.00 100
10 20 20 1.00 100
5 20 20 1.00 100
1 20 18 0.90 90
0.50 20 7 0.35 35
0.10 20 2 0.10 10
0.05 20 1 0.05 5
A probit analysis of the Abbott RealTime MTB data determined that the concen-
tration of MTB detected with 95% probability was 2.45 cfu/mL at CN cutoff 40 (95%
Conﬁdence Interval of 1.44e6.10 cfu/mL). The claimed LOD is 17 cfu/mL.(Table 3). The results showed no interference in the performance of
the Abbott RealTime MTB assay in the presence of high levels of
blood, DNA from human cells, gastric acid, hypertonic saline,
physiological saline, culture media, NALC pellet material and ﬁveMycobacterium kansasii Chromobacterium
violaceum
Staphylococcus
haemolyticus
Mycobacterium lentiﬂavum Chlamydia
pneumoniae
Staphylococcus hominis
Mycobacterium marinum Chlamydia
trachomatis
Streptococcus agalactiae
Mycobacterium neoaurum Citrobacter freundii Streptococcus gordonae
Mycobacterium
nonchromogenicum
Corynebacterium
diphtheriae
Streptococcus mitis
Mycobacterium phlei Corynebacterium
xerosis
Streptococcus mutans
Mycobacterium
pneumoniae
Cryptococcus
neoformans
Streptococcus pneumoniae
Mycobacterium pulveris Cytomegalovirus Streptococcus pyogenes
Mycobacterium
scrofulaceum
Enterobacter
aerogenes
Streptomyces griseinus
Mycobacterium shimoidei Enterobacter cloacae Varicella-zoster virus
Mycobacterium simiae Enterococcus faecalis Veillonella parvula
Mycobacterium smegmatis Enterococcus avium
Table 3
Potential interfering substances and their concentrations/percentages tested to
determine susceptibility to interfering substances.
Potentially interfering
substance
Specimen source Concentration/percentage
Mucus Sputum Mucin 5% (w/v)
Blood Sputum or BAL 5% (v/v)
DNA from human cells Sputum, BAL, NALC
Sediments of
Sputum/BAL
106 cells/mL
Gastric acid Sputum/BAL pH 3e4 HCl in water,
neutralized to pH 6e8 with
sodium bicarbonate
Hypertonic saline used
to induce sputum
Sputum NaCl (5% w/v)
Physiologic saline
used to collect BAL
BAL NaCl (0.9% w/v)
Culture media MTB culture 100%
Material used to
resuspend NALC
pellets
NALC pellets 0.067 M phosphate,
pH 6.8
Isoniazid (anti-TB
medication)
Sputum or BAL 90 mg/mL
Rifampicin/rifampin
(anti-TB
medication)
Sputum or BAL 120 mg/mL
Streptomycin(Anti-
TB medication)
Sputum or BAL 400 mg/mL
Pyrazinamide (anti-
TB medication)
Sputum or BAL 500 mg/mL
Ethambutol (anti-TB
medication)
Sputum or BAL 60 mg/mL
Table 4
Sensitivity and speciﬁcity obtained when testing clinical specimens.
Culture/smear results
Sensitivity Speciﬁcity
Cþ/Sþ Cþ/S Cþ C
RealTime MTB 99% (147/149) 81% (51/63) 93% (198/212) 97% (348/359)
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azinamide, Ethambutol). Interference of the Abbott RealTime MTB
assay was observed in the presence of bovinemucus at 8.3% (all ﬁve
replicates were false negative or inhibited) and 5.0% (one of ﬁve
replicates was false negative). No interference was found at bovine
mucus concentrations of 2.5% or less (data not shown).
3.5. Carryover
To evaluate the potential of carryover from high positive MTB
samples to negative samples when using the Abbott RealTime MTB
assay, ﬁve m2000 system runs each consisting of 96 samples
(Positive Control, Negative Control, 46 high positive samples at
1  107 copies/mL and 46 negative samples) in which the high
positive samples were interspersed among negative samples. The
MTB concentration in the high positive sample of 1 107 copies/mL
resulted in a Ct value that was earlier than 95% or more of the re-
sults obtained from specimens of the MTB positive population
tested with Abbott RealTime MTB assay (data not shown). The
Abbott RealTime MTB assay did not exhibit any carryover from high
positive samples to the 230 negative samples in the ﬁve runs (data
not shown). A 96 sample run was completed in less than 8 h.
3.6. Reproducibility
A reproducibility test was performed to evaluate the Abbott
RealTime MTB assay repeatability in the m2000 system and the
compatibility between the Abbott m2000sp instrument and the
manual sample preparation method. The study was performed
with a positive panel at three times the claimed LOD level and
a negative panel. The study was conducted by four operators using
two lots of Abbott RealTime MTB ampliﬁcation reagents: two
operators performing runs using an Abbott m2000sp instrument
and two operators performing runs using manual sample prepa-
ration. For each sample preparation method, the two operatorseach used one unique lot of Abbott RealTime MTB ampliﬁcation
reagents and tested each panel member in replicates of eight,
once per day, for ﬁve days, for a total of 40 replicates per panel
member (80 total replicates per panel member per method; 160
total tested with m2000sp instrument sample preparation and 160
total tested with manual sample preparation). The overall agree-
ment for Abbott RealTime MTB with expected results was 100%
(159/159, one sample was invalid because of an instrument error)
with a lower 95% CI of 98.1% for samples prepared with the Abbott
m2000sp instrument or with manual sample preparation (data not
shown). The Abbott RealTime MTB assay is compatible with both
the Abbott m2000sp instrument and the Abbott manual sample
preparation method.
3.7. Clinical sensitivity and speciﬁcity
One sputum or one NALC sediment was tested from each of
582 TB suspect patients. Samples were collected from Russia, South
Africa, Uganda, the United States, and Vietnam. Each specimenwas
split to allow testing of Abbott RealTime MTB on one aliquot and
smear and culture on the second aliquot. The testing samples were
blinded and ﬁnal result decoding was performed by AM statistical
group. For Abbott RealTime MTB testing, two specimens generated
an invalid IC result, and an additional four specimen results gave
m2000 error codes. The frequency of clinical specimens with
invalid results measured by inhibition was 0.3% (2/582), while the
invalid rate including both inhibition and instrument errors was
1.0% (6/582). Five culture negative specimens that were positive by
both Abbott RealTime MTB and a commercially available MTB NAAT
were excluded from the analysis. A total of 571 valid samples were
included for data analysis. The overall Abbott RealTime MTB
sensitivity versus culture was 93% (198/212). The assay sensitivity
was 99% (147/149) in smear positive, culture positive specimens,
and 81% (51/63) in smear negative, culture positive samples. The
speciﬁcity was 97% (348/359) (Table 4). 76 of the MTB negative
samples contained Non-TuberculousMycobacteria (NTM). Of these,
38 were MAC (Mycobacterium avium complex), seven were Myco-
bacterium gordonae, ﬁve were Mycobacterium kansasii, ﬁve were
Mycobacterium chelonae/abscessus, three were Mycobacterium
xenopi, and 18 contained other mycobacterial species. With Abbott
RealTime MTB assay, all of the NTM sample results were “MTB Not
Detected” with the exception of two samples that produced “MTB
Detected” results with late CN (>38) values as compared to the
assay cutoff of 40. The speciﬁcity value of 97% resulted from testing
the NTM population is similar to the speciﬁcity observed when
testing the non-NTM population (data not shown). Furthermore
500 non-TB suspect patient sputum samples collected from within
the U.S. population showed 100% TB negative test results with the
Abbott RealTime MTB assay (data not shown).
4. Discussion
The Abbott RealTime MTB assay was developed to detect MTB in
sputum, BAL, and NALC sediments of sputum and BAL collected
from TB suspect patients. The assay is performed on the m2000
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96 samples (Positive Control, Negative Control, and one to 94 pa-
tient specimens) per run. Manual sample preparation is also an
option. An inactivation step is performed to liquefy sputum sample
and reduce infectivity of MTB in specimens before processing the
specimens on the m2000 and thereby reduces the chance of the
operators of the system being infected with MTB [10]. Data has
been generated demonstrating that the Abbott RealTime MTB
inactivation method is capable of inactivating high concentrations
of MTB in culture samples, as well as in clinical specimens [11].
For Abbott RealTime MTB two different MTB-speciﬁc primer/
probe sets are used: the ﬁrst set was designed to detect the multi-
copy insertion element, IS6110 [5], and second set, the single copy
gene, PAB [8]. Because there have been reports of MTB strains that
lack IS6110 [9], or that have a deletion in the PAB gene [12], the use
of both targets minimizes the risk of false negative results. The data
generated in this paper suggest that the dual target strategy used
for Abbott RealTime MTB results in the detection of MTB genomic
DNA with high reliability.
The mycobacterial cell wall is resistant to conventional cell lysis
techniques due to the complex structure of lipophilic molecules
and polysaccharides. Abbott RealTime MTB sample preparation
uses a guanidinium thiocyanate-magnetic microparticle puriﬁca-
tion method with optimized incubation temperatures and mixing
conditions for TB cell lyses and genomic DNA release. Early opti-
mization studies showed that the RealTime MTB assay sample DNA
extraction method is comparable in efﬁciency to mechanical bead
beating for TB cell lyses (data not shown).
All 66 MTB complex DNAs (including eight different MTB com-
plex species) were detected by Abbott RealTime MTB. Mycobacte-
rium mungi [13] and Mycobacterium orygis [14], two relatively
newly identiﬁed MTB complex sub-species, were not tested.
Because both of these MTB sub-species contain IS6110, and because
of the dual target strategy used for Abbott RealTime MTB, it is ex-
pected that Abbott RealTime MTB will detect both of these sub-
species. The analytical sensitivity of the assay was evaluated by
using MTB strain H37Rv. The study demonstrating that the LOD for
Abbott RealTime MTB was 17 cfu/mL (with 99% conﬁdence).
Reliability of the automated Abbott RealTime MTB was assessed
in four ways. First, speciﬁcity of the Abbott RealTimeMTB assay was
assessed by testing 80 potentially different cross-reactors. None of
the potential cross-reactors were detected. Second, a carryover
assessment was performed in which high positive MTB samples
were processed alongside negative samples to determine if false
positives, or carryover, were detected in the negative samples. No
false positives were observed, suggesting that carryover will not be
an issue. Third, various potentially interfering substances were
tested for their impact on assay performance. No interference was
observed, except with 8.3% and 5.0% bovine mucus, where inter-
ference was observed. This interference was removed when the
mucus concentration was reduced to 2.5%. When clinical speci-
mens were tested, the rate of specimens with invalid IC results was
0.3% demonstrating that Abbott RealTime MTB sample preparation
removed PCR inhibitors in an effective manner. This provides evi-
dence of the robustness of the protocol and suggests that the
impact of interference caused by bovine mucus is likely not sig-
niﬁcant to the assay. Finally, a reproducibility study was performed
in which multiple users used multiple m2000 instrument systems,
or manual sample preparation, to test low positive (three times
LOD) and negative panels. 100% reproducibility was observed.
These data suggest that Abbott RealTime MTB is robust when used
in analytical studies and clinical samples testing.
The clinical utility of Abbott RealTime MTB was assessed by
testing sputum and NALC specimens collected from patients sus-
pected of having TB in ﬁve countries using both archived samplesand prospectively collected samples. Overall assay sensitivity was
93%, while it was 99% in smear positive culture positive samples
and 81% in smear negative culture positive samples. Speciﬁcity was
97%. The results of the analytical speciﬁcity test and the sputum
sample testing from non-TB suspect population from within the
U.S. all showed 100% speciﬁcity. The Abbott RealTime MTB assay
clinical speciﬁcity was determined based on comparison of assay
results with culture results. A comparison against culture results
was used because at present culture results are still considered as
the gold standard in TB detection. The main reason for the lower
speciﬁcity observed in the study (97%) is the fundamental differ-
ence between the two techniques that were used. For example,
growth of MTB cells in culture may be inhibited due to over pro-
cessing of samples during the NALC decontamination process that
is required prior to culture [15]. Furthermore, the sampling popu-
lation in this study may contain patients under therapy. In these
patients, culture negative sputum samples may still contain dead
TB cells which are detected with NAATs. A third possibility is the
detection of latent TB. A majority of the negative sputum samples
for the validation study were collected from Uganda and Vietnam
from very high TB prevalence areas. In these areas, there is a high
probability of having latent TB patients with culture negative
sputum samples containing very low MTB cell counts. Therefore,
inhibition of the growth of MTB in culture due to the effect of
processing on the respiratory specimen and/or the low numbers of
organisms in the sample rather than the result being a true false
positive may explain the difference in observed speciﬁcity between
the TB suspect population and the non-TB suspect population.
Furthermore, the UNITAID Tuberculosis Diagnostic Technology
Landscape semi-annual update released in Dec. 2012 [16] proposed
a minimum set of speciﬁcations for the design of any new POC
diagnostic test for MTB: “Speciﬁcity e adults, 95% compared to
culture”. Abbott RealTime MTB, with a speciﬁcity of 97% compared
to culture, surpassed this requirement.
The performance of Abbott RealTime MTB in detecting pauci-
bacillary samples from MTB-HIV co-infected patients needs to be
determined [17]. Additional studies are ongoing to test the per-
formance of Abbott RealTime MTB in the clinical setting. Abbott
RealTime MTB is performed using the m2000™ system analyzer, a
system that is capable of running multiple assays including Abbott
RealTime HIV, thus enabling management of MTB-HIV co-infected
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